



Final Appraisal Recommendation
Advice No: 2616 – September 2016

Rilpivirine (Edurant®) 25 mg film-coated tablets

Limited submission by Janssen-Cilag Ltd

Recommendation of AWMSG

Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients from 12 years old to < 18 years old with a viral load $\leq 100,000$ HIV-1 RNA copies/ml.

Additional note:

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2936), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Janssen-Cilag Ltd
Date of first issue	September 2016
Last reviewed	July 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2616:
Rilpivirine (Edurant®) 25 mg film-coated tablets. September 2016.